Business & FinanceHealth

Reuters ahead with U.S. pursuing nearly $13 billion in claims in Purdue Pharma opioid probes

Reuters was well ahead in reporting that U.S. prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company’s alleged role in fueling the nation’s opioid crisis. The Justice Department is among thousands of creditors vying to extract money from Purdue, which has a liquidation value of only a bit more than $2 billion. Purdue has offered to settle widespread opioid litigation in a deal it values at more than $10 billion. 

Article Tags
Topics of Interest: Business & FinanceHealth
Type: Reuters Best
Sectors: Equities
Regions: North America
Win Types: Speed
Story Types: Exclusive / Scoop
Media Types: Text
Sign up for email updates

Sign up for email updates